A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. (2021)
Attributed to:
G2P-UK; A National Virology Consortium to address phenotypic consequences of SARSCoV-2 genomic variation
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41467-021-25480-z
PubMed Identifier: 34552091
Publication URI: http://europepmc.org/abstract/MED/34552091
Type: Journal Article/Review
Volume: 12
Parent Publication: Nature communications
Issue: 1
ISSN: 2041-1723